Abstract
Introduction
Gabapentin (GBP), I-(aminomethyl) cyclohexane-acetic acid, is a cyclic y-aminobutyric acid (GABA) analog originally designed to mimic the steric conformation of GABA [22] , to have high lipid solubility to penetrate the blood-brain barrier, and to be a centrally active GABA agonist with potential therapeutic value [19] . GBP has been shown to have anticonvulsant activity in a variety of animal seizure models [3] and is effective in the treatment of human partial [5, 7, 11, 23] and generalized tonic-clonic seizures [5, 7] . Despite its effectiveness against a variety of seizures, GBP's *Corresponding author.
antiepileptic mechanism of action remains unknown.
There are relatively few reported electrophysiological studies directed at determining GBP's antiepileptic mechanism of action. The present study used a variety of cultured rodent neuronal preparations and electrophysiological techniques including intracellular, whole cell, and single channel recordings to determine any effects of GBP on inhibitory (GABA and glycine) and excitatory (N-methyl-Daspartate (NMDA) and non-NMDA) amino acid neurotransmitter receptors, repetitive tiring of sodium (Na+) action potentials, and on voltage-dependent calcium (Ca2') channel currents. GBP was tested at or above plasma concentrations which range N 12-88 ,uM in ongoing clinical stu-dies [6] . These studies were chosen to corroborate or confirm the results of other studies suggesting an effect of GBP on excitatory or inhibitory neurotransmitter systems, or on voltage-dependent ion channels. Preliminary results from;the present experiments have been reported previously [ 13,261.
removed, placed in MEM, centrifuged, triturated, recentrifuged, resuspended, plated, reincubated, and 1 ml of MEM was added to each plate after 30 min. Nodose and DRG neurons were used after _ 1 h of incubation and were viable for -12 h.
Experiments

Methods
I. Cultures
I. I. Cortical neurons.
Cortices were removed from E 18 rat fetuses, treated with trypsin (type 1, bovine pancreas, Sigma) and mechanically dissociated. Neurons were suspended in MEM supplemented with glucose 30 mM, bicarbonate 26 mM, 10% fetal calf serum and 10% horse serum and were plated on poly+lysine-coated culture dishes. 5-Fluoro-2-deoxyuridine (15 pg/ml) and uridine (35 pg/ml) in MEM were added to cultures on the fifth day. Cultures were maintained for 2-5 weeks prior to experiments.
Spinal cord neurons.
Spinal cords were dissected from E 12-14 mouse fetuses, minced, mechanically dissociated, and plated. Growth media consisted of MEM supplemented with 5.5 g glucose and 1.5 g NaHCOj per liter, sera as above and adjusted to 325 mOsm. The cultures were incubated at 35°C in a 90% air/IO% CO* atmosphere. The NaC03/C02 buffer was maintained at pH 7.4. 5-Fluoro-2-deoxyuridine was added to cultures after 68 days. Cultures were maintained for at least 4 weeks prior to experiments.
Sensory neurons.
Nodose ganglia were taken from 5-10 days old rats, placed in oxygenated Ca2+-and Mgzf -free DPBS, treated with collagenase (type lA, Sigma) (1 mg/ml), and incubated at 37°C in a 93% sir/7% CO2 atmosphere for 30 min. Following addition of 5% fetal calf serum, the neurons were triturated, centrifuged, resuspended in MEM, plated in collagen-coated dishes, and reincubated prior to use. Dorsal root ganglia (DRG) were taken from 15-25 day old rats (-20/animal), placed in MEM, minced, treated with collagenase (3 mg/ml), and incubated for 50 min before trypsin (1 mg/ml) was added for 10 min. The ganglia were 2.2.1. Inhibitory and excitatory amino acids.
Intracellular recordings of spinal cord or cortical neurons were made with glass micropipettes (2s 60 MQ) tilled with 3 M KC1 (GABA and glycine) or 4 M KAc (glutamate).
Membrane potential was recorded with a high-impedance bridge amplifier and recorded on analog tape. The recording solution contained (in mM): NaCl 140, KC1 5, MgClz 10, CaC12 1, glucose 10, pH 7.3-7.4. GABA (0.5 M, pH 3.2, positive current), glycine (0.5 M, pH 3.0, positive current), or glutamate (0.4 M, pH 10, negative current) was applied by passing 400 ms current pulses every 5 s from a high resistance micropipette placed -2 pm from the impaled neuron. Retaining current (negative for GABA and glycine, positive for glutamate) was applied to prevent leakage between pulses. Membrane potential was hyperpolarized to -60 to -80 mV. Iontophoretic current was adjusted so that responses were approximately 10 mV in amplitude. GBP was applied by pressure ejection (0.25 1.0 psi, 30 s) from blunt-tipped (10 pm) micropipettes placed 3&100 pm from the neuron. NMDA (10 PM) was applied by pressure ejection (10 s, 1 psi) in the presence or absence of GBP or glycine. Data were expressed as percentage of control amplitude but were not used if the response failed to return to control levels after drug application.
NMDA single channel currents.
The external solution for single channel experiments consisted of (in mM): NaCl 142, KC1 1.5, CaC12 1, glucose 10, Na'-HEPES 10 (pH 7.4, -300-320 mOsm). The internal pipette solution consisted of (in mM): CsCl 153, Cs'-HEPES 10, EGTA 5 (pH 7.4, -280-305 mOsm). NMDA (Sigma) and glytine (Sigma) were dissolved in external solution (lo-100 PM) and serially diluted to final concentrations. Glycine concentrations were expressed as the amount of glycine added to the external solu- High resistance GQ seals were obtained with glass micropipettes (5-10 MS2) for outside-out excised patch recordings. Recordings were performed with a L/M EPC-7 amplifier (LIST-Medical Instruments) and currents were recorded on a video cassette system via a digital audio processor (16 bit, 44 kHz). Currents were simultaneously displayed on a chart recorder using a lowpass (3 db at 1 kHz) S-pole Bessel filter. Data were played back from the VCR system through a lowpass filter (3 db at 2 kHz) and digitized (20 kHz, 16 bit) for computer analysis. System dead time was 70 ps, so only openings > 140 ~.ls (2 x system dead time) were considered valid openings.
Single channel data were analyzed by computer using a locally written channel detection program (50% threshold crossing criterion) and locally written analysis programs used to determine opening frequency, and open and closed durations. Percent change in opening frequency was determined in those patches where control solution (NMDA alone) was applied before, during and after application of GBP. Openings from the two higher conductance levels of NMDA receptor single channel currents (40 and 50 pS) were analyzed. To elicit repetitive firing, 450 ms depolarizing current pulses of varying amplitudes were used. If a neuron fired action potentials throughout any of the 450 ms pulses, tiring was judged as sustained. A neuron was used when the resting membrane potential was -40 mV or more negative and had overshooting action potentials.
All experiments were conducted at 35-37°C. GBP was dissolved in recording solution and was applied to the bath. Neurons were tested at membrane potentials of approximately -50 mV for the ability to fire sustained action potentials. Data were expressed as the percentage of neurons showing sustained firing. Because recordings were done with a low concentration of Mg*+ in the recording solution, synaptically driven action potentials were recorded when neurons were held at resting potential (-50 to -60 mV). Effects of GBP on spontaneous action potentials were qualitatively assessed and cells were judged to have either normal or reduced levels of spontaneous action potentials.
Voltage-dependent Ca2+ channel currents.
Recordings
of Ca*+ currents were made with glass micropipettes (1.5-2.5 MQ) filled with a solution of (in mM): CsCl 140, CsOH 30, HEPES 10, EGTA 10, ATP 5 and GTP 0.1, pH 7.2-7.3, N 300 mOsm. Neurons were bathed in a solution of (in mM): choline Cl 67, TEA 100, glucose 5.6, KC1 5.3, CaC12 5.0, MgC12 0.8, HEPES 10, pH 7.35, -320 mOsm. Following sealing of the micropipette to the neuron and rupture of the membrane patch, the neuron was hyperpolarized to a holding potential (V,) = -90 mV.
The program pCLAMP (Axon Instruments) was used to generate voltage step commands and to digitize (5.6 kHz) and store current traces. All experiments were conducted at room temperature. GBP was prepared on the day of experiments as described above and put in external solution. The GBP solution was drawn up into a blunt tipped (15-20 pm) micropipette and lowered to -50 pm from the neuronal soma and applied by passive diffusion or pressure ejection (1 psi) shortly before and during voltage step commands. T currents were isolated by evoking currents from a Vh = -90 mV at clamp potentials (V,) at or positive to -55 mV (typically, V, = -65 to -20 mV). N/L currents were evoked from a Vi, = -80 or -90 mV at a V, at or positive to -20 mV. T and N/L currents were measured at the point of peak inward current and at 100 ms, and were leak subtracted for analysis. In order to distinguish between the N and L components qualitatively, currents were evoked at V, = -10 mV from Vh = -80 mV and -40 mV. Current evoked from Vh = -40 mV was used as an estimate of L current and the additional current evoked from Vi, = -80 mV was used as an estimate of N current. Ethosuximide (1 mM) was used to block T current; nifedipine (10 PM) was used to block L current; w-conotoxin GVIA (10 ,uM) was used to block N current. Each was applied by passive diffusion from blunt tipped (35-50 PM) micropipettes positioned -50 pm from the neuronal soma prior to voltage step commands.
3. Results
GBP did not affect membrane potential
GBP (18-500 PM) did not affect membrane potential upon direct application to spinal cord neurons (N = 20). No depolarization or hyperpolarization was noted upon application, unlike the action of agonists that interact with GABA* or glutamate receptors which produce depolarization or hyperpolarization, depending upon recording conditions. These results suggest that GBP is not acting as an agonist at inhibitory or excitatory amino acid receptors in spinal cord neurons.
GBP did not affect inhibitory amino acid responses
Iontophoretic application of GABA or glycine, with 3 M KC1 in the recording electrode, resulted in a depolarization of membrane potential. Iontophoretic ejection current was adjusted to produce depolarization of approximately 10 mV. GBP (18-500 PM) applied by pressure ejection did not reduce the amplitude of GABA-or glycine-evoked depolarizations ( Fig. 1 , Table 1 ). Diazepam (100 nM) increased the amplitude of iontophoretic GABA responses by 81% (N = 5) in a similar preparation.
GBP had variable effects on excitatory amino acid responses
Iontophoretic application of glutamate in the presence of Mg2+ (10 mM) activates both a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainate subtypes of postsynaptic glu- tamate receptors. GBP (175 PM) applied by pressure ejection had no effect on the amplitude of iontophoretic glutamate responses (Fig. 1 , Table  1 ). Pentobarbital (200 PM) reduced the amplitude of glutamate responses by 16% (N = 5). However, GBP (100 PM) had a variable effect on the responses of cortical neurons when applied with NMDA (Table 1, Fig. 2 ). In the absence of added glycine, GBP enhanced the amplitude of the sustained portion of NMDA-evoked responses in seven of 18 neurons with an average increase of 59% ( Fig. 2A) . Eleven of 18 cells showed no enhancement (~20% change from control) of NMDA responses by 100 ,LM GBP (Fig. 2B) . Glytine was effective in enhancing NMDA-evoked depolarizations in all neurons tested with the addition of glycine (1 PM) enhancing the amplitude of the sustained portion of NMDA-evoked depolarizations by 212% (N = 4).
GBP did not enhance NMDA-evoked depolarizations in the presence of glycine. With glycine (1 ,nM), GBP at 100 PM (106% of control, N = 6) or at 1 mM (104% of control, N = 10) was not effective in enhancing NMDA-evoked depolarizations when applied by pressure ejection. Application of 1 mM GBP by superfusion was also ineffective in affecting NMDA-evoked depolarizations (106 f 3.1% control, N= 5). At higher concentrations of NMDA (25 PM) and glycine (10 PM), GBP at 10 ,LM (107 f 9.8% control, N= 5) and 100 PM (104 f 7.5% control) had no effect on the amplitude of the sustained portion of the NMDA-evoked depolarizations.
GBP did not reduce the amplitude of NMDAevoked depolarizations under any of the conditions tested. However, NMDA (10 PM) responses could be completely blocked by the competitive NMDA antagonist 3-(( f. )-2-carboxypiperazin-4-yl)-propyl-1 -phosphonic acid (CPP) (100 PM, N = 3) and the amplitude of the sustained portion of NMDA-evoked depolarizations was reduced to 9 f 4.5% of control by the glycine site partial agonist HA-966 (500 PM, N = 6).
Single channel recordings of NMDA receptor currents from excised outside-out patches were made to further investigate the possibility of an interaction between GBP and NMDA receptors. In the absence of added glycine NMDA (5 PM) evoked single channel openings at a frequency of 2.2/s. Addition of 1 mM GBP did not increase the frequency of openings (1.4/s) in these patches but the frequency of NMDA receptor channel openings was increased 5-fold (10.4/s) by the addition of 2.5 PM glycine (N=4 patches). In the presence of 2.5 PM glycine, GBP (1 mM) did not change average open duration (2.6 ms control, 2.5 ms GBP), opening frequency (10.7/s control, 9.9/s GBP), burst duration (6.7 ms control, 7.5 ms GPB), the number of openings/burst (1.7 control, 1.9 GBP) or the burst frequency (6.0/s control, 5.3/ s GBP) (N = 6 patches, 28949159 openings, 1682-4824 bursts, Fig. 3 ). GBP did not alter the amplitude of NMDA receptor single channel openings in the presence or absence of glycine (Fig. 3) . These data indicate that GBP does not act like an agonist or partial agonist at the glycine site of the NMDA receptor, having no effect on the frequency of channel openings, and that GBP also had no effect on the kinetics of NMDA receptor single channels. greatly increased the frequency of channel opening. In the presence of NMDA and glycine (B), addition of GBP (I mM) had no effect on the kinetics of single channel openings.
GBP did not block sustained repetitive firing of
Nai action potentials or synaptically driven action potentials
Control neurons (N = 17) responded to 4.50 ms depolarizations with trains of action potentials that were sustained throughout the depolarization (Fig. 4, left panel) . Addition of GBP (18-175 PM) to the bathing solution for l&30 min had no effect on the sustained repetitive firing of action potentials (Table 2 , Fig. 4, right panel) . In experiments performed in low Mg2 ' (1 mM), the effect of GBP on spontaneous synaptically driven action poten- tials was evaluated. Bath application of GBP ( 18-175 PM) had no effect on spontaneous action potentials (Table 2) .
3.5. GBP did not ajjhct Ca' ' channel currents GBP (I mM) was tested for effects on Ca2+ channel currents in nodose and dorsal root ganglion neurons (N = 18). Low threshold (T) and high threshold (N/L) currents were examined individually. GBP had no effect on peak current, current at 100 ms, or on apparent current activation or inactivation (Fig. 5) . Individual Ca2+ channel currents were reduced by the application of specific blockers. Ethosuximide (1 mM) reduced peak T current (16%, N = 3). Nifedipine (10 PM) reduced L current (30% of evoked current from Vh = -40 mV at a V, = -10 mV, N = 3). w-Conotoxin (10 PM) reduced N current (45% of evoked current from Vh = -90 mV at V, = -10 mV, N = 3) (data not shown). 
Discussion
GBP was designed to have a steric conformation similar to GABA and to have high lipid solubility to penetrate the blood-brain barrier for potential therapeutic value as a GABA agonist. GBP has shown potent anticonvulsant activity in a variety of animal seizure models and is effective in treating human partial and generalized tonic-clonic seizures. Several types of experimental studies have been performed to determine the nature of GBP's antiepileptic effects. These studies include possible interaction with ligand-and voltage-gated ions channels. Inhibitory and excitatory amino acid receptor systems have been examined extensively without conclusive results. Fewer studies have been directed at voltage-gated ion channels yielding negative or inconclusive results.
Inhibitory amino acid systems
Early work suggested that GBP may act on GABA systems since it protected mice from tonic extension in chemical convulsion models directed at inhibition of GABA synthesis (3-mercaptopropionic acid. isonicotinic acid, semicarbazide) or inhibition at the GABA* receptor complex (bicuculline, picrotoxin) [2, 4] Nat channels suggest that GBP does not interact directly with Na+ channels (C. Taylor, personal communication).
Voltage-dependent Ca2' channel currents are involved in numerous physiologic functions of the neuron. L currents are involved in the presynaptic release of neurotransmitters, N currents may be primary regulators of the inhibition of release of neurotransmitters or neuromodulators, and T currents are probably responsible for the low threshold Ca2+ spike that underlies some neuronal oscillatory bursting behavior. T currents may also be involved in the generation of thalamocortical rhythms such as sleep spindles, and possibly, the abnormal electroencephalographic 3 Hz spike and wave rhythm seen in human absence seizures. Although GBP is most effective in the treatment of human partial and generalized tonic-clonic seizures, the effect of GBP on absence seizures has been studied both in animal models of absence seizures and as add-on therapy in drug-resistant epileptic patients. In animal studies using pentylenetetrazol-induced clonic seizures, GBP protected mice from clonic convulsions in both the S.C. Metrazol test (EDso 147 mg/kg) and the i.v. threshold test (120% control, 30-50 mg/kg) [3] . However, in a rat genetic model of absence epilepsy, GBP increased electroencephalographic spike and wave bursts in a dosedependent manner at 25 and 100 mg/kg [9] . In studies of mouse spinal cord neurons, GBP blocked responses to Bay K 8644, an agonist at the dihydropyridine binding site of the L channel [28] . In human studies, GBP reduced > 50% of absence seizures in half of the patients in one study [5] , and in another study, GBP reduced absence seizures and generalized spike and wave complexes in patients undergoing 24 h EEG monitoring [20] .
In the present studies, GBP did not affect any component of the Ca*+ channel current subtype studied (T, L, or N). Since GBP did not affect residual current following use of both nifedipine and w-conotoxin, there was no evidence to suggest that GBP might be capable of blocking P-type Ca*+ channel current. These results suggest that GBP's basic mechanism of action was not on voltage-dependent Ca*+ channels.
In summary, the results of the present studies do not demonstrate a major effect of GBP on any of the several different experimental systems tested, even when tested at concentrations well above plasma concentrations which commonly range N 12-88 PM in clinical studies [6] . Specifically, the studies do not show significant effects of GBP on neuronal responses to applied GABA, glycine, or glutamate. At high concentrations, GBP shows a variable enhancement of NMDA responses, however, GBP produces no reductions in NMDA responses under the conditions tested. GBP does not show effects on sustained repetitive firing of Nat channel action potentials or on voltage-dependent Ca*+ channel currents. Each of the experimental systems tested specific voltage-or ligand-gated responses that previous animal and/or human studies suggested as potentially important in the mechanism of action of GBP. Our results fail to corroborate the results of previous investigations other than those which were similar in design and yielded negative results. The mechanism of action of GBP on neurons involved in the generation of seizure activity remains to be determined.
